Table 2.

IIEF scale scores compared to the baseline values

		Treatment Group
		Saffron (n=34)				Placebo (n=34)
FSFI domain	week	MD*	SEMD	95% CI		MD*	SEMD	95% CI
				LL	UL			LL	UL
Total Score	2 weeks	5.81	0.90	3.98	7.65	5.28	0.85	3.55	7.02
	4 weeks	7.17	0.90	5.34	9.00	5.30	0.94	3.39	7.21
	6 weeks	8.66	1.00	6.62	10.71	5.61	1.03	3.51	7.71
Desire	2 weeks	0.99	0.16	0.66	1.31	0.49	0.14	0.20	0.77
	4 weeks	1.31	0.18	0.96	1.67	0.61	0.17	0.27	0.95
	6 weeks	1.36	0.22	0.92	1.81	0.67	0.15	0.37	0.97
Arousal	2 weeks	1.07	0.22	0.63	1.51	0.76	0.17	0.41	1.10
	4 weeks	1.29	0.21	0.86	1.73	0.88	0.16	0.56	1.21
	6 weeks	1.47	0.22	1.03	1.91	1.06	0.21	0.64	1.49
Lubrication	2 weeks	0.83	0.21	0.39	1.26	0.70	0.18	0.33	1.07
	4 weeks	1.34	0.24	0.86	1.82	0.75	0.19	0.37	1.14
	6 weeks	1.65	0.25	1.15	2.15	0.89	0.19	0.50	1.27
Orgasmic Function	2 weeks	1.22	0.24	0.73	1.72	1.05	0.18	0.68	1.41
	4 weeks	1.45	0.25	0.94	1.97	1.03	0.22	0.58	1.48
	6 weeks	1.74	0.24	1.26	2.23	1.14	0.22	0.69	1.60
Satisfaction	2 weeks	1.21	0.24	0.73	1.70	0.97	0.20	0.56	1.38
	4 weeks	1.58	0.23	1.10	2.05	0.96	0.21	0.53	1.40
	6 weeks	1.94	0.24	1.45	2.42	0.98	0.21	0.56	1.41
Pain	2 weeks	0.92	0.20	0.51	1.32	1.03	0.26	0.50	1.56
	4 weeks	1.16	0.20	0.76	1.56	0.82	0.26	0.30	1.34
	6 weeks	1.35	0.22	0.90	1.81	0.88	0.28	0.32	1.44

FSFI, Female Sexual Function Index; MD, mean difference; SEMD, standard error of mean difference; CI, confidence interval; LL, lower limit; UL, upper limit.

*MD postbaseline value baseline value